Figure 2
From: Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses
The antiviral activities of TPNT1 against SARS-CoV-2 in vitro. (a) Inhibition of plaque formation in the presence of serially diluted TPNT1. (b)The half maximal effective concentration (EC50) and cell toxicity of TPNT1 for Vero E6 cells was determined by plaque reduction assay and ACP assay, respectively. (c) Plaque reduction assay of TPNT1(1:50 dilution) against various SARS-CoV-2 strains. (d) The percentage of inhibition by plaque reduction assay in (c). (e) Inhibition of virus titers in the supernatants of SARS-CoV-2 infected H1975-ACE2 cells by TPNT1. (f) Inhibition of viral nucleocapsid (NP) protein expression in TPNT-1 treated SARS-CoV-2 infected H1975-ACE2 cells. The ratio of NP to the internal loading control, proliferating cell nuclear antigen (PCNA), was shown below each blot. At least three independent experiments were performed and one representative result was shown. Full-length blots/gels of (f) were presented in Supplementary Fig. 1.
